Detalimogene Clinical Development Programs
enGene’s investigational therapy is a novel, non-viral gene therapy being studied in the LEGEND Clinical Trial.

enGene Therapeutics develops non-viral genetic medicines for mucosal tissues, with detalimogene voraplasmid a gene therapy in a pivotal trial.
engene.comCrawled Nov 14, 2026
enGene’s investigational therapy is a novel, non-viral gene therapy being studied in the LEGEND Clinical Trial.
enGene develops localized, non-viral gene therapies, such as detalimogene for NMIBC, to reduce treatment burden and improve patient outcomes.
enGene develops localized, non-viral gene therapies, including detalimogene for NMIBC, to reduce treatment burden and improve outcomes.
enGene is developing localized, non-viral gene therapy, including detalimogene for NMIBC, to reduce treatment burden and improve patient outcomes.
BOSTON & MONTREAL – enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a virtual key opinion leader
Business combination transaction completed with Forbion European Acquisition Corp. Clinical stage biotechnology company with EG-70 lead program in pivotal clinical study targeting BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) $138M in
83% of patients evaluable for efficacy achieved Complete Response (CR) at 3-months No Dose-Limiting Toxicities or Serious Adverse Events have been reported in the study Adverse Events (AEs) were limited
Interim Phase 1 results from enGene’s Phase 1/2 LEGEND study of intravesical EG-70 (detalimogene voraplasmid) demonstrate a 71% CR rate at three months in patients with high-grade non-muscle invasive bladder
BOSTON, MA and MONTREAL, Feb. 2, 2023 – enGene, Inc., a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX
BOSTON and MONTRÉAL, March 17, 2022 – enGene Inc., a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform,
BOSTON and MONTREAL, Sept. 7, 2023 – enGene, Inc., a clinical-stage biotechnology company mainstreaming gene therapy through its novel platform for the delivery of therapeutics to mucosal tissues and other
enGeneers advance non-viral gene therapy to improve patient outcomes and offer career opportunities.
enGeneers advance non-viral gene therapy to improve patient outcomes and provide career growth opportunities.
Amy Pott is Chief Global Commercialization Officer at enGene Therapeutics Inc.
Anthony T. Cheung, PhD is the Co-Founder & Chief Scientific Officer at enGene Therapeutics Inc.
Jill Buck is Chief Development Officer at enGene Holdings Inc.
Joan Connolly is the Chief Technology Officer at enGene Therapeutics Inc.
Matthew Boyd is Chief Regulatory Officer at enGene Holdings Inc.
Tara Place is Senior Vice President, Human Resources at enGene Holdings Inc.
enGene is led by experts in drug development and commercialization across oncology, urology, and other therapeutic areas.
enGene is led by experts in drug development and commercialization across oncology, urology and several other therapeutic areas.
enGeneers work to advance non-viral genetic medicines and improve patient outcomes.
enGeneers advance non-viral genetic medicines to improve patient outcomes.
enGene advances detalimogene, a non-viral gene therapy for non-muscle invasive bladder cancer (NMIBC), to reduce treatment burden and improve outcomes.
enGene reports updated efficacy data from its LEGEND trial for **Detalimogene** in **BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC)**. The primary endpoint of **complete response (CR) at any time** rises to **56%** (from 54% in April 2026). Key secondary metrics also improve, including a **≥12-month duration of response (DoR) estimate at 43%** (up from 25%) and a **median DoR of 10.1 months** (from 8.6 months). The **12-month CR rate** reaches **24%** (up from 13%). The company plans to submit a **Biologics License Application (BLA)** for Detalimogene by year-end.
enGene Therapeutics appoints **Erik T. Goluboff, MD, MBA** as Chief Medical Officer and **Jason Duncan** as Chief Legal and Administrative Officer. The company issues inducement equity grants to both executives ahead of its planned **biologics license application (BLA) submission for detalimogene** before the end of 2026. Approval for the gene therapy is anticipated in 2027.
enGene reports progress in its **LEGEND program**, with key regulatory milestones nearing completion, including **complete response (CR) durability data** and **landmark CR rates** expected in late 2026. The company is preparing for a **pre-Biologics License Application (BLA) meeting with the FDA** and plans to initiate a **BLA submission for detalimogene** in the fourth quarter. A **surfactant plus detalimogene safety cohort** has successfully completed its run-in phase, with a planned webinar on preclinical data and enrollment guidance.
enGene reports updated interim results from its LEGEND pivotal trial, showing a **54% complete response (CR) rate** among patients at any time and a **43% six-month CR rate**. The study also highlights a **3.2% progression rate to muscle-invasive or higher disease**, with **55% of patients experiencing treatment-related adverse events (TRAEs)**, most of which were mild. Only **2.4% of patients** required treatment interruption or discontinuation due to TRAEs. The Kaplan-Meier estimate projects a **12-month CR rate of 25%**.
enGene Holdings Inc. priced a $130 million public offering of 12.6 million common shares at $8.50 each and pre-funded warrants for 2.7 million shares at $8.4999 each. The transaction includes underwriting discounts and commissions. The company specializes in clinical-stage, non-viral genetic medicines.
enGene’s experimental therapy **detalimogene** achieves a **62% complete response rate at 6 months** in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer. The **LEGEND trial’s pivotal cohort** of **125 patients** completes enrollment, exceeding targets, while reporting low treatment-related adverse events (42%) and minimal dose interruptions (1.6%). Early data suggest potential first-line use for this patient group.
enGene Holdings raises **$60 million** through a private placement of **6.76 million common shares** to advance its lead investigational product, **detalimogene voraplasmid (EG-70)**, currently in a pivotal trial for **high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)** with carcinoma in situ (CIS). The funding supports late-stage development of the non-viral genetic medicine, which targets patients unresponsive to standard BCG therapy. enGene, a clinical-stage biotech, lists on Nasdaq under the ticker **ENGN**.
enGene secures a fully subscribed $200 million private placement from new and existing investors. The company, specializing in genetic medicines, expects the funds to support its operating plan through 2027. enGene’s lead program, EG-70, is currently in a pivotal study targeting BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
enGene secures a $50 million debt facility from Hercules Capital, advancing $22.5 million immediately. The four-year loan supports the company’s clinical-stage genetic medicines, including its lead program EG-70 targeting BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The facility expands enGene’s financial flexibility as it progresses pivotal studies for its therapeutic candidates.
enGene Holdings Inc. debuts on Nasdaq as a publicly traded biotech company specializing in genetic medicines. The firm secures **$138 million** in gross proceeds from a business combination with Forbion European Acquisition Corp., funding its **EG-70** lead program—a pivotal clinical study for **BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)**. EG-70 is currently enrolling patients, while enGene expands its pipeline into additional therapeutic areas.